Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
Notified -
Globe Newswire23-05-2025, 04:05
MoveEV Launches First-of-its-Kind AI-Driven Employee 28-02-2023, 20:52